[1]张 续,赵莉平,安 荣.肠易激综合征生物标志物研究进展[J].陕西医学杂志,2022,51(8):1038-封3.[doi:DOI:10.3969/j.issn.1000-7377.2022.08.031]
 ZHANG Xu,ZHAO Liping,AN Rong.Research progress on biomarkers of irritable bowel syndrome[J].,2022,51(8):1038-封3.[doi:DOI:10.3969/j.issn.1000-7377.2022.08.031]
点击复制

肠易激综合征生物标志物研究进展
分享到:

《陕西医学杂志》[ISSN:1000-7377/CN:61-1281/TN]

卷:
51
期数:
2022年8期
页码:
1038-封3
栏目:
综 述
出版日期:
2022-08-05

文章信息/Info

Title:
Research progress on biomarkers of irritable bowel syndrome
作者:
张 续赵莉平安 荣
(陕西中医药大学,陕西 咸阳 712046)
Author(s):
ZHANG XuZHAO LipingAN Rong
(Shaanxi University of Chinese Medicine,Xianyang 712046,China)
关键词:
肠易激综合征 生物标志物 诊断 炎性因子 粪便钙卫蛋白
Keywords:
Irritable bowel syndrome Biomarker Diagnosis Inflammatory factor Fecal calprotectin
分类号:
R 574
DOI:
DOI:10.3969/j.issn.1000-7377.2022.08.031
文献标志码:
A
摘要:
肠易激综合征(IBS)是以脑-肠调节紊乱,内脏高敏感性为特征的慢性消化系统常见疾病,也是公认的一种具有特殊病理生理基础的心身疾病。其诊断主要依赖罗马Ⅳ诊断标准,该标准主观性较强,容易造成误诊或者漏诊。因此,寻找一种诊断效能较高的生物学标记物是目前 IBS 临床诊疗面临的挑战之一。现从血液生物标志物、粪便生物标志物、结肠黏膜免疫标志物、病原体标志物和分子生物学标志物5个方面,就近年来IBS相关生物标志物的研究现状作一综述,以期为临床工作者更好的了解和应用提供帮助。
Abstract:
Irritable bowel syndrome(IBS)is a common chronic digestive disease characterized by brain gut regulation disorder and visceral hypersensitivity.It is also recognized as a psychosomatic disease with special pathophysiological basis.Its diagnosis mainly depends on Rome Ⅳ diagnostic standard,which is highly subjective and easy to cause misdiagnosis or missed diagnosis.Therefore,finding a biomarker with high diagnostic efficiency is one of the challenges faced by the clinical diagnosis and treatment of IBS.This paper reviews the research status of IBS related biomarkers in recent years from five aspects:blood biomarkers,fecal biomarkers,colonic mucosal immune markers,pathogen markers and molecular biomarkers,in order to provide help for clinical workers to better understand and apply.

参考文献/References:

[1] Szymaszkiewicz A,Storr M,Fichna J,et al.Enkephalinase inhibitors,potential therapeutics for the future treatment of diarrhea predominant functional gastrointestinal disorders[J].Neurogastroenterol Motil,2019,31(4):13526.
[2] Nakov R,Sarafov S,Gospodinova M,et al.Transthyretin amyloidosis:Testing strategies and model for center of excellence support[J].Clin Chim Acta,2020,509:228-234.
[3] Lembo AJ,Neri B,Tolley J,et al.Use of serum biomarkers in a diagnostic test for irritable bowel syndrome[J].Aliment Pharmacol Ther,2009,29(8):834-842.
[4] Wang P,Du C,Chen FX,et al.Bdnf contributes to ibs-like colonic hypersensitivity via activating the enteroglia-nerve unit[J].Scientific Reports,2016,6:20320.
[5] Senkal E,Durankus F,Cam S,et al.Increased serum bdnf and probdnf levels in children with irritable bowel syndrome[J].J Psychosom Res,2020,137:110216.
[6] Kim JH,Lin E,Pimentel M.Biomarkers of irritable bowel syndrome[J].J Neurogastroenterol Motil,2017,23(1):20-26.
[7] Fan W,Fei G,Li X,et al.Sera with anti-enteric neuronal antibodies from patients with irritable bowel syndrome promote apoptosis in myenteric neurons of guinea pigs and human sh-sy5y cells[J].Neurogastroenterol Motil,2018,30(12):13457.
[8] Zaki MES,Elhammady D,Foda Salama M,et al.Study of antibodies to cytolethal distending toxin b(cdtb)and antibodies to vinculin in patients with irritable bowel syndrome[J].F1000 Res,2021,10:303.
[9] Patel SR,Singh A,Misra V,et al.Levels of interleukins 2,6,8,and 10 in patients with irritable bowel syndrome[J].Indian J Pathol Microbiol,2017,60(3):385-389.
[10] 张 瑜,张 露,李 双,等.超敏C反应蛋白在不同亚型肠易激综合征的表达及其与炎症因子的相关性 [J].世界华人消化杂志,2020,28(16):782-788.
[11] Sheikhesmaili F,Jalili A,Taghizadeh E,et al.The ccl28 levels are elevated in the serum of patients with irritable bowel syndrome and associated with the clinical symptoms[J].Am J Clin Exp Immunol,2021,10(1):23-29.
[12] Hayatbakhsh MM,Gowhari SA,Pishgouyi S,et al.The serum levels of ccl2 and ccl16 expression in patients with irritable bowel syndrome[J].Rep Biochem Mol Biol,2019,8(1):9-14.
[13] 程宏辉,周福生.顺激方治疗肠易激综合征30例及对T细胞亚群的影响[J].陕西中医,2009,30(7):835-836.
[14] 马 军,韩棉梅,宋雨鸿.乌梅丸联合中药敷贴治疗寒热错杂型肠易激综合征疗效及对TH1/TH2细胞因子的影响[J].陕西中医,2017,38(2):212-216.
[15] Singh P,Silvester J,Chen X,et al.Serum zonulin is elevated in ibs and correlates with stool frequency in ibs-d [J].United European Gastroenterol J,2019,7(5):709-715.
[16] Massier L,Chakaroun R,Kovacs P,et al.Blurring the picture in leaky gut research:How shortcomings of zonulin as a biomarker mislead the field of intestinal permeability[J].Gut,2021,70(9):1801-1802.
[17] Lyutakov I,Nakov R,Valkov H,et al.Serum levels of fibroblast growth factor 19 correlate with the severity of diarrhea and independently from intestinal inflammation in patients with inflammatory bowel disease or microscopic colitis[J].Turk J Gastroenterol,2021,32(4):374-381.
[18] Mumolo MG,Bertani L,Ceccarelli L,et al.From bench to bedside:Fecal calprotectin in inflammatory bowel diseases clinical setting[J].World J Gastroenterol,2018,24(33):3681-3694.
[19] Dai C,Jiang M,Sun MJ.Fecal markers in the management of inflammatory bowel disease[J].Postgrad Med,2018,130(7):597-606.
[20] Krarup AL,Engsbro A,Fassov J,et al.Danish national guideline:Diagnosis and treatment of irritable bowel syndrome[J].Dan Med J,2017,64(6):5382.
[21] 邢 晨,潘逼然,单 晶,等.粪便钙卫蛋白与肠易激综合征患者临床特征的相关性[J].西部医学,2020,32(7):1020-1023.
[22] 张宪波,刘月皎,陈云峰.粪便钙卫蛋白在肠易激综合征和炎症性肠病鉴别诊断中的意义分析[J].现代检验医学杂志,2021,36(1):124-127.
[23] Campbell JP,Zierold C,Rode AM,et al.Clinical performance of a novel liaison fecal calprotectin assay for differentiation of inflammatory bowel disease from irritable bowel syndrome[J].J Clin Gastroenterol,2021,55(3):239-243.
[24] Freeman K,Taylor-Phillips S,Willis BH,et al.Test accuracy of faecal calprotectin for inflammatory bowel disease in uk primary care:A retrospective cohort study of the imrd-uk data[J].BMJ Open,2021,11(2):44177.
[25] Sidhu R,Wilson P,Wright A,et al.Faecal lactoferrin-a novel test to differentiate between the irritable and inflamed bowel[J].Aliment Pharmacol Ther,2010,31(12):1365-1370.
[26] Zhou XL,Xu W,Tang XX,et al.Fecal lactoferrin in discriminating inflammatory bowel disease from irritable bowel syndrome:A diagnostic meta-analysis[J].BMC Gastroenterol,2014,14:121.
[27] Carrasco-Labra A,Lytvyn L,Falck-Ytter Y,et al.Aga technical review on the evaluation of functional diarrhea and diarrhea-predominant irritable bowel syndrome in adults(ibs-d)[J].Gastroenterology,2019,157(3):859-880.
[28] Zhernakova A,Kurilshikov A,Bonder MJ,et al.Population-based metagenomics analysis reveals markers for gut microbiome composition and diversity[J].Science(New York NY),2016,352(6285):565-569.
[29] Gacesa R,Vich VA,Collij V,et al.A combination of fecal calprotectin and human beta-defensin 2 facilitates diagnosis and monitoring of inflammatory bowel disease [J].Gut Microbes,2021,13(1):1943-1949.
[30] Burns G,Carroll G,Mathe A,et al.Evidence for local and systemic immune activation in functional dyspepsia and the irritable bowel syndrome:A systematic review[J].Am J Gastroenterol,2019,114(3):429-436.
[31] Berg LK,Goll R,Fagerli E,et al.Intestinal inflammatory profile shows increase in a diversity of biomarkers in irritable bowel syndrome[J].Scand J Gastroenterol,2020,55(5):537-542.
[32] 李毓玲,张 国,梁运啸,等.腹泻型肠易激综合征患者体内CD4+T淋巴细胞亚群的分布及其诊断意义[J].广西医学,2020,42(16):2069-2075.
[33] Salvo-Romero E,Martínez C,Lobo B,et al.Overexpression of corticotropin-releasing factor in intestinal mucosal eosinophils is associated with clinical severity in diarrhea-predominant irritable bowel syndrome[J].Scientific Reports,2020,10(1):20706.
[34] Robles A,Perez ID,Myneedu K,et al.Mast cells are increased in the small intestinal mucosa of patients with irritable bowel syndrome:A systematic review and meta-analysis[J].Neurogastroenterol Motil,2019,31(12):13718.
[35] Zhang Y,Qin G,Liu DR,et al.Increased expression of brain-derived neurotrophic factor is correlated with visceral hypersensitivity in patients with diarrhea-predominant irritable bowel syndrome[J].World J Gastroenterol,2019,25(2):269-281.
[36] Nejati S,Wang J,Heredia-Rivera U,et al.Small intestinal sampling capsule for inflammatory bowel disease type detection and management[J].Lab Chip,2021,22(1):57-70.
[37] Jeffery IB,Das A,O'Herlihy E,et al.Differences in fecal microbiomes and metabolomes of people with vs without irritable bowel syndrome and bile acid malabsorption[J].Gastroenterology,2020,158(4):1016-1028.
[38] Liu Y,Li W,Yang H,et al.Leveraging 16s rrna microbiome sequencing data to identify bacterial signatures for irritable bowel syndrome[J].Front Cell Infect Microbiol,2021,11:645951.
[39] Morales W,Rezaie A,Barlow G,et al.Second-generation biomarker testing for irritable bowel syndrome using plasma anti-cdtb and anti-vinculin levels[J].Dig Dis Sci,2019,64(11):3115-3121.
[40] Vasapolli R,Schulz C,Schweden M,et al.Gut microbiota profiles and the role of anti-cdtb and anti-vinculin antibodies in patients with functional gastrointestinal disorders(fgid)[J].Eur J Clin Invest,2021,51(12):13666.
[41] Das A,O'Herlihy E,Shanahan F,et al.The fecal mycobiome in patients with irritable bowel syndrome[J].Scientific Reports,2021,11(1):124.
[42] Jabbar KS,Dolan B,Eklund L,et al.Association between brachyspira and irritable bowel syndrome with diarrhoea[J].Gut,2021,70(6):1117-1129.
[43] Park JH.Dysregulated microrna expression in irritable bowel syndrome[J].J Neurogastroenterol Motil,2016,22(2):166-167.

相似文献/References:

[1]樊 盼,陆建荣,姚俊涛△.颗粒蛋白前体在肿瘤发生和发展中的作用研究进展[J].陕西医学杂志,2020,49(7):910.[doi:DOI:10.3969/j.issn.10007377.2020.07.039]
 FAN Pan,LU Jianrong,YAO Juntao..Research progress on the role of progranulin in tumors[J].,2020,49(8):910.[doi:DOI:10.3969/j.issn.10007377.2020.07.039]
[2]康文玥,杨淑梅,遆嬿羽,等.嗜酸性粒细胞与慢性阻塞性肺疾病相关性研究进展[J].陕西医学杂志,2021,50(8):1034.[doi:DOI:10.3969/j.issn.1000-7377.2021.08.033]
[3]王 琛,齐广莹.Borealin在肿瘤中的作用及其分子机制研究进展[J].陕西医学杂志,2021,50(8):1038.[doi:DOI:10.3969/j.issn.1000-7377.2021.08.034]
[4]李博文,张心宇,刘 洋,等.肺腺癌患者血清长链非编码RNA miR155HG表达及意义[J].陕西医学杂志,2022,51(4):492.[doi:DOI:10.3969/j.issn.1000-7377.2022.04.026]
 LI Bowen,ZHANG Xinyu,LIU Yang,et al.Expression and significance of lncRNA miR155HG in serum of patients with lung adenocarcinoma[J].,2022,51(8):492.[doi:DOI:10.3969/j.issn.1000-7377.2022.04.026]
[5]韦佩祺,苏梓健,梁 芳,等.microRNA在系统性红斑狼疮中的作用机制研究进展[J].陕西医学杂志,2023,52(2):238.[doi:DOI:10.3969/j.issn.1000-7377.2023.02.027]
 WEI Peiqi,SU Zijian,LIANG Fang,et al.Research progress on the mechanism of microRNA in systemic lupus erythematosus and the intervention of traditional Chinese medicine[J].,2023,52(8):238.[doi:DOI:10.3969/j.issn.1000-7377.2023.02.027]
[6]谢琼燕,许环清,叶 文,等.生物标志物预测脓毒症引发急性肾损伤临床研究[J].陕西医学杂志,2023,52(7):880.[doi:DOI:10.3969/j.issn.1000-7377.2023.07.024]
 XIE Qiongyan,XU Huanqing,YE Wen,et al.Clinical study of using biomarkers to predict acute kidney injury induced by sepsis[J].,2023,52(8):880.[doi:DOI:10.3969/j.issn.1000-7377.2023.07.024]
[7]任佳容,张 芸.环状RNA在心血管疾病中的研究进展[J].陕西医学杂志,2023,52(10):1446.[doi:DOI:10.3969/j.issn.1000-7377.2023.10.038]

备注/Memo

备注/Memo:
基金项目:陕西省科技计划项目(2020JM-592); 陕西省教育厅专项教学研究计划项目(17JK0197); 陕西省中医药科研课题(15-JC004); 陕西中医药大学重点培育科研基金资助项目(2015PY18)
更新日期/Last Update: 2022-08-04